AI-driven Clairity Breast platform, now FDA-approved, predicts five-year breast cancer risk from mammograms, enhancing early ...

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and ...

ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST U.S. FDA approves third indication of darolutamide for patients ...

The U.S. Food and Drug Administration has approved the humanized monoclonal antibody Zynyz (retifanlimab-dlwr) as the first ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received previous treatment, the drugmaker said on Wednesday.

The US Food and Drug ... FDA has also granted accelerated approval to AbbVie’s Emrelis for the treatment of previously treated, locally advanced or metastatic non-squamous non–small-cell lung ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

The FDA becomes involved before any new drug molecule is tested in humans. Here’s how upheaval at the agency appears to be affecting specific points in the approval process for new drugs.

Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian cancer with KRAS mutations. The United States Food and Drug Administration ...

according to the American Cancer Society. The FDA's accelerated approval of Emrelis was based on a mid-stage trial of 84 patients, where the drug showed an overall response rate of 35%.

The US Food and Drug Administration has approved ... be announced within the next month. The American Cancer Society applauded the new FDA approval. “Despite the benefits of cervical cancer ...

An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib ...